News & Updates

Bloodstream infections rarely occur in children hospitalized for influenza but are associated with intensive care unit (ICU) admission, mechanical ventilation, longer hospital stay, and higher in-hospital mortality, according to a study.

Patients with hepatitis B virus (HBV) infection are at heightened risk of latent tuberculosis (TB), while those with latent TB are also at increased risk of HBV infection, reveals a study. Notably, the risk of co-infection is highest among Asians and those born in high-incidence countries.

Birth month is predictive of influenza vaccination timing in young children, owing to its impact on the scheduling of preventive care visits, reports a US study. Specifically, children born in October are more likely to be vaccinated in the same month and less likely to be diagnosed with influenza, supporting recommendations that promote October vaccination.

Forced sedentary behaviour, brought about by the COVID-19 lockdown, has negative effects on the metabolic and inflammatory profile of many teenagers, which can potentially lead to long-term poor health outcomes, suggests a study.

Long COVID may have contributed to reduced participation in the UK labour market, a cohort study suggests.

In the IMPAACT* P1115 study presented at CROI 2024, four children who received antiretroviral therapy (ART) for HIV very early in life remained free of detectable HIV for over a year after a break in their ART regimen.

Remdesivir may cut the risk of symptoms and diagnoses associated with possible post-COVID conditions (PCC), otherwise known as long COVID.

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.